Neuropeptide Systems and Schizophrenia

Author(s): Amber L. LaCrosse , M. Foster Olive .

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 12 , Issue 5 , 2013

Become EABM
Become Reviewer

Abstract:

Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.

Keywords: Schizophrenia, antipsychotic, dopamine, neuropeptide, positive symptoms, negative symptoms, cognitive deficits.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 5
Year: 2013
Page: [619 - 632]
Pages: 14
DOI: 10.2174/1871527311312050010
Price: $58

Article Metrics

PDF: 26